KRAS and neoplasm: The engrafted tumors showed decreased expression of tumor cell‐derived, pro‐oncogenic cytokines IL‐1β and IL‐6, suggesting that ruxolitinib interferes with feed‐forward cytokine signaling which promotes K‐RAS tumorigenesis.10 Furthermore, ruxolitinib treatment resulted in tumor growth reduction in immunocompetent experimental mouse models.